Therapeutic Advances in the Treatment of Glioblastoma: Rationale and Potential Role of Targeted Agents

Therapeutic Advances in the Treatment of Glioblastoma: Rationale and Potential Role of Targeted Agents David A. Reardon, Patrick Y. Wen Oncologist 2006; 11: 152-164 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in the field of Neuro-Oncology and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Describe the genetic alterations frequently observed in GBM tumors as well as the cell signal transduction pathways that are aberrantly activated in these tumors. Discuss the clinical benefit recently associated with temozolomide chemotherapy for patients with GBM. Identify mediators of signal transduction pathways that are attractive targets of novel therapeutics in GBM patients. Understand the potential benefit associated with regionally administered therapies for GBM patients as a means to overcome drug delivery limitations into the central nervous system caused by the blood-brain barrier. Describe the rationale for combination regimens incorporating novel targeted agents for GBM patients. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Feb. 13, 2006 Most Recent Review: May 8, 2007* Most Recent Update: Feb. 13, 2006 Date Credit Expires: Feb. 13, 2008 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.